Efficacy of recombinant human adenovirus-p53 combined with chemotherapy for locally advanced cervical cancer: A clinical trial.

摘要: The aim of this study was to evaluate the efficacy and safety recombinant human adenovirus-p53 (rhAd-p53) combined with neoadjuvant chemotherapy in treatment locally advanced cervical cancer (LACC). A total 40 patients LACC (stage IB2 IIIA) were randomized into 2 groups (n=20 each): PVB group (cisplatin + vincristine bleomycin, intravenously) (rhAd-p53 gene therapy chemotherapy). Both underwent a course chemotherapy; only exception injection rhAd-p53 solution 1×1012 VP intratumorally at an interval three days thrice thereafter. tumor sizes adverse events both observed. expression vascular endothelial growth factor (VEGF), protein p53 micro-vessel density (MVD) tissue respectively determined by immunohistochemistry. evaluation performed weeks after completion chemotherapy. 75% versus 95% group; size reduced 11.42±2.78 cm2 significant shrinkage 15.25±4.00 (P<0.05). VEGF, MVD downregulated groups, significantly statistical differences control. No additional evidenced group. Therefore, intratumoral has advantage over conventional for its high efficacy, synergism LACC.